Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25070058 | 0.79 | CHRM1 (0.35) | ATMTRPA1JAK3MAPT | |
| SCHEMBL20696886 | 0.79 | CHRM1 (0.35) | ATMTRPA1JAK3MAPT | |
| SCHEMBL20696753 | 0.79 | CHRM1 (0.35) | ATMTRPA1JAK3MAPT | |
| SCHEMBL20696891 | 0.79 | CHRM1 (0.35) | ATMTRPA1JAK3MAPT | |
| SCHEMBL15380366 | 0.78 | TRPA1 (0.34) | EPHX2TRPA1JAK3MAPTEPHX1 | |
| SCHEMBL16144313 | 0.77 | TBK1 (0.32) | EPHX2 | |
| SCHEMBL18347985 | 0.77 | DPP4 (0.38) | EPHX1SMN1; SMN2 | |
| SCHEMBL20696898 | 0.74 | TYK2 (0.33) | ATMJAK3 | |
| SCHEMBL20688132 | 0.74 | TYK2 (0.33) | ATMJAK3 | |
| SCHEMBL21245979 | 0.74 | TYK2 (0.33) | ATMJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | EPHX2 2636/4885ATM 1773/4885TRPA1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.